Physician profile
Megen Yerman
NPI 1053944298
$1,874.78
in general payments reported to CMS, 2019-2025
18 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $253 · 2023: $545 · 2024: $341 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.58 |
| Education | $119.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $452.89 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $389.79 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $227.53 | 2021-2025 | Invega, Spravato |
| Otsuka America Pharmaceutical, INC. | $136.59 | 2021-2024 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $122.17 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $120.61 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.76 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $60.19 | 2024-2025 | Hetlioz, Fanapt |
| Corium, LLC | $39.02 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $34.80 | 2022-2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $32.21 | 2025 | Cobenfy |
| Lundbeck LLC | $28.31 | 2023-2024 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $27.50 | 2023 | Auvelity |
| Tempus Ai, INC | $26.65 | 2024 | |
| Avanir Pharmaceuticals, INC. | $26.29 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $16.27 | 2023 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $14.00 | 2024 | Qelbree |
| Noven Therapeutics, LLC | $13.20 | 2023 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megen Yerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.